541 related articles for article (PubMed ID: 16650951)
41. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
Burgess DS; Frei CR
J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
[TBL] [Abstract][Full Text] [Related]
42. Multicentre study of the in vitro activity of cefepime, a broad-spectrum cephalosporin, compared to other broad-spectrum agents.
Bell JM; Turnidge JD;
Pathology; 2001 Feb; 33(1):53-60. PubMed ID: 11280610
[TBL] [Abstract][Full Text] [Related]
43. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012).
Farrell DJ; Sader HS; Flamm RK; Jones RN
Int J Antimicrob Agents; 2014 Jun; 43(6):533-9. PubMed ID: 24856078
[TBL] [Abstract][Full Text] [Related]
44. In vitro activities of antimicrobials against six important species of gram-negative bacteria isolated from raw milk samples in Korea.
Nam HM; Lim SK; Kim JM; Joo YS; Jang KC; Jung SC
Foodborne Pathog Dis; 2010 Feb; 7(2):221-4. PubMed ID: 19895257
[TBL] [Abstract][Full Text] [Related]
45. Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000).
Jones RN; Kirby JT; Beach ML; Biedenbach DJ; Pfaller MA
Diagn Microbiol Infect Dis; 2002 Jul; 43(3):239-43. PubMed ID: 12106958
[TBL] [Abstract][Full Text] [Related]
46. Multicenter evaluation of antimicrobial resistance to six broad-spectrum beta-lactams in Colombia using the Etest method. The Colombian Antimicrobial Resistance Study Group.
Jones RN; Salazar JC; Pfaller MA; Doern GV
Diagn Microbiol Infect Dis; 1997 Dec; 29(4):265-72. PubMed ID: 9458984
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of current activities of fluoroquinolones against gram-negative bacilli using centralized in vitro testing and electronic surveillance.
Sahm DF; Critchley IA; Kelly LJ; Karlowsky JA; Mayfield DC; Thornsberry C; Mauriz YR; Kahn J
Antimicrob Agents Chemother; 2001 Jan; 45(1):267-74. PubMed ID: 11120976
[TBL] [Abstract][Full Text] [Related]
48. In vitro evaluation of cefepime and other broad-spectrum beta-lactams against bacteria from Indonesian medical centers. The Indonesia Antimicrobial Resistance Study Group.
Lewis MT; Biedenbach DJ; Jones RN
Diagn Microbiol Infect Dis; 1999 Dec; 35(4):285-90. PubMed ID: 10668587
[TBL] [Abstract][Full Text] [Related]
49. Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States.
Koomanachai P; Bulik CC; Kuti JL; Nicolau DP
Clin Ther; 2010 Apr; 32(4):766-79. PubMed ID: 20435246
[TBL] [Abstract][Full Text] [Related]
50. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Moet GJ; Jones RN; Biedenbach DJ; Stilwell MG; Fritsche TR
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):7-13. PubMed ID: 17059876
[TBL] [Abstract][Full Text] [Related]
51. Inducible amp C beta-lactamase producing gram-negative bacilli from blood stream infections: frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE).
Pfaller MA; Jones RN; Marshall SA; Coffman SL; Hollis RJ; Edmond MB; Wenzel RP
Diagn Microbiol Infect Dis; 1997 Aug; 28(4):211-9. PubMed ID: 9327251
[TBL] [Abstract][Full Text] [Related]
52. Trends in antimicrobial susceptibilities among bacterial pathogens isolated from patients hospitalized in European medical centers: 6-year report of the MYSTIC Surveillance Study (1997-2002).
Turner PJ
Diagn Microbiol Infect Dis; 2005 Apr; 51(4):281-9. PubMed ID: 15808320
[TBL] [Abstract][Full Text] [Related]
53. Antimicrobial activity of cefepime tested against Bush group I beta-lactamase-producing strains resistant to ceftazidime. A multilaboratory national and international clinical isolate study.
Jones RN; Marshall SA
Diagn Microbiol Infect Dis; 1994 May; 19(1):33-8. PubMed ID: 7956010
[TBL] [Abstract][Full Text] [Related]
54. In vitro activity of garenoxacin tested against a worldwide collection of ciprofloxacin-susceptible and ciprofloxacin-resistant Enterobacteriaceae strains (1999-2004).
Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2007 May; 58(1):27-32. PubMed ID: 17383140
[TBL] [Abstract][Full Text] [Related]
55. Activity of levofloxacin and ciprofloxacin in combination with cefepime, ceftazidime, imipenem, piperacillin-tazobactam and amikacin against different Pseudomonas aeruginosa phenotypes and Acinetobacter spp.
Drago L; De Vecchi E; Nicola L; Colombo A; Guerra A; Gismondo MR
Chemotherapy; 2004 Oct; 50(4):202-10. PubMed ID: 15452399
[TBL] [Abstract][Full Text] [Related]
56. Piperacillin/Tazobactam: Evaluation of Its In vitro Activity against Bacteria Isolated in Two Brazilian Hospitals and an Overview of Its Antibacterial Activity, Pharmacokinetic Properties and Therapeutic Potential.
Sader HS; Ferreira AT; Tosin I; Gales AC; Keim LS; Carbadillo JM; Mello SJ; Tavares W
Braz J Infect Dis; 1998 Oct; 2(5):241-255. PubMed ID: 11103015
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of antimicrobial susceptibility for beta-lactams using the Etest method against clinical isolates from 100 medical centers in Japan (2006).
Ishii Y; Tateda K; Yamaguchi K;
Diagn Microbiol Infect Dis; 2008 Feb; 60(2):177-83. PubMed ID: 17931820
[TBL] [Abstract][Full Text] [Related]
58. Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance.
Jones RN; Kirby JT; Rhomberg PR
Diagn Microbiol Infect Dis; 2008 Jun; 61(2):203-13. PubMed ID: 18329835
[TBL] [Abstract][Full Text] [Related]
59. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003).
Fritsche TR; Stilwell MG; Jones RN
Clin Microbiol Infect; 2005 Dec; 11(12):974-84. PubMed ID: 16307551
[TBL] [Abstract][Full Text] [Related]
60. The Meropenem Yearly Susceptibility Test Information Collection antimicrobial susceptibility program in Spain: a 5-year analysis.
Pascual A; Perea E; Alvarez M; Casal M; Garcia de Lomas J; Garcia RodrÃguez JA; Martin R; Soria G; Zapardiel J;
Diagn Microbiol Infect Dis; 2007 Feb; 57(2):195-200. PubMed ID: 17052882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
